Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Literature DB >> 24565562

Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Jennifer R Ribeiro¹, Richard N Freiman².

Abstract

Resistance to anti-estrogen therapies is a prominent challenge in the treatment of ovarian cancer. Tumors develop endocrine resistance by acquiring adaptations that help them rely on alternative oncogenic signaling cascades, which crosstalk with estrogen signaling pathways. An understanding of estrogen signaling crosstalk with these growth promoting cascades is essential in order to maximize efficacy of anti-estrogen treatments in ovarian cancer. Herein, we provide an overview of estrogen signaling in ovarian cancer and discuss the major challenges associated with anti-estrogen therapies. We also review what is currently known about how genomic and non-genomic estrogen signaling pathways crosstalk with several major oncogenic signaling cascades. The insights provided here illustrate existing strategies for targeting endocrine resistant ovarian tumors and may help identify new strategies to improve the treatment of this disease.

Entities: CellLine Chemical Disease Gene Species

Keywords: Endocrine resistance; Estradiol; Estrogen receptor; Estrogen signaling; Ovarian cancer

Mesh：

Substances：
Estrogens

Year: 2014 PMID： 24565562 PMCID： PMC4127339 DOI： 10.1016/j.jsbmb.2014.02.010

Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN： 0960-0760 Impact factor: 4.292

185 in total

Review 1. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Authors: Xiaoyong Fu; C Kent Osborne; Rachel Schiff
Journal: Breast Date: 2013-09-05 Impact factor: 4.380

2. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Authors: Dana Faratian; Annelien J M Zweemer; Yoko Nagumo; Andrew H Sims; Morwenna Muir; Michael Dodds; Peter Mullen; Inhwa Um; Charlene Kay; Max Hasmann; David J Harrison; Simon P Langdon
Journal: Clin Cancer Res Date: 2011-05-13 Impact factor: 12.531

3. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.

Authors: Xin Ge; Ruixia Guo; Yuhuan Qiao; Yancai Zhang; Jia Lei; Xinyan Wang; Liuxia Li; Dongmei Hu
Journal: Int J Gynecol Cancer Date: 2013-01 Impact factor: 3.437

4. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.

Authors: Mohammed Tanjimur Rahman; Kentaro Nakayama; Munmun Rahman; Hiroshi Katagiri; Atsuko Katagiri; Tomoka Ishibashi; Masako Ishikawa; Kouji Iida; Satoru Nakayama; Yoshiro Otsuki; Kohji Miyazaki
Journal: Am J Clin Pathol Date: 2012-10 Impact factor: 2.493

5. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.

Authors: Lingeng Lu; Dionyssios Katsaros; Andrew Wiley; Irene A Rigault de la Longrais; Harvey A Risch; Manuela Puopolo; Herbert Yu
Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531

6. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.

Authors: P Pujol; J M Rey; P Nirde; P Roger; M Gastaldi; F Laffargue; H Rochefort; T Maudelonde
Journal: Cancer Res Date: 1998-12-01 Impact factor: 12.701

7. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.

Authors: Song Yi Ko; Nicolas Barengo; Andras Ladanyi; Ju-Seog Lee; Frank Marini; Ernst Lengyel; Honami Naora
Journal: J Clin Invest Date: 2012-09-04 Impact factor: 14.808

8. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

Authors: A Berchuck; G C Rodriguez; A Kamel; R K Dodge; J T Soper; D L Clarke-Pearson; R C Bast
Journal: Am J Obstet Gynecol Date: 1991-02 Impact factor: 8.661

9. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

Authors: Jill Bayliss; Amy Hilger; Prakash Vishnu; Kathleen Diehl; Dorraya El-Ashry
Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531

10. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.

Authors: Emily M Fox; Carlos L Arteaga; Todd W Miller
Journal: Front Oncol Date: 2012-10-16 Impact factor: 6.244

16 in total

1. Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development.

Authors: Robert Callahan; Barry A Chestnut; Ahmed Raafat
Journal: Exp Biol Med (Maywood) Date: 2016-08-21

2. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.

Authors: Chun Wai Ng; Kwong-Kwok Wong
Journal: J Ovarian Res Date: 2022-05-24 Impact factor: 5.506

Review 10. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.

Authors: Nicole E James; Clinton Chichester; Jennifer R Ribeiro
Journal: Front Oncol Date: 2018-04-24 Impact factor: 6.244

Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Review 1. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

2. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

3. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.

4. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.

5. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.

6. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.

7. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.

8. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

9. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

10. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.

1. Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development.

2. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.

Review 3. Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations.

Review 4. Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies.

5. Estrogen accelerates the resolution of inflammation in macrophagic cells.

Review 6. Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.

7. Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration.

8. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.

Review 9. Role of RUNX2 in Breast Carcinogenesis.

Review 10. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.